GW&K Investment Management LLC Has $1.85 Million Position in Krystal Biotech, Inc. $KRYS

GW&K Investment Management LLC lessened its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 65.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 10,492 shares of the company’s stock after selling 19,683 shares during the period. GW&K Investment Management LLC’s holdings in Krystal Biotech were worth $1,852,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Sound View Wealth Advisors Group LLC increased its holdings in Krystal Biotech by 2.9% in the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 2,003 shares of the company’s stock valued at $354,000 after buying an additional 56 shares during the period. Bessemer Group Inc. increased its stake in Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after acquiring an additional 77 shares during the period. Arizona State Retirement System raised its position in Krystal Biotech by 1.3% in the third quarter. Arizona State Retirement System now owns 6,397 shares of the company’s stock worth $1,129,000 after purchasing an additional 81 shares in the last quarter. Main Management ETF Advisors LLC raised its position in Krystal Biotech by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 5,131 shares of the company’s stock worth $705,000 after purchasing an additional 84 shares in the last quarter. Finally, M&T Bank Corp lifted its stake in Krystal Biotech by 2.3% during the second quarter. M&T Bank Corp now owns 3,785 shares of the company’s stock worth $520,000 after purchasing an additional 85 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of recent research reports. Weiss Ratings raised Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, February 18th. Jefferies Financial Group raised their target price on Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. TD Cowen reaffirmed a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. The Goldman Sachs Group upped their price target on Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Finally, Bank of America increased their price objective on Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Krystal Biotech has a consensus rating of “Moderate Buy” and a consensus price target of $326.25.

Krystal Biotech Price Performance

KRYS stock opened at $253.69 on Friday. The business has a fifty day moving average price of $269.86 and a 200 day moving average price of $218.28. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $298.30. The stock has a market capitalization of $7.42 billion, a price-to-earnings ratio of 37.04 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The company had revenue of $107.11 million for the quarter, compared to analysts’ expectations of $105.30 million. On average, equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total transaction of $6,580,250.00. Following the sale, the insider directly owned 1,403,155 shares of the company’s stock, valued at $369,324,427.55. This represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the completion of the transaction, the chief accounting officer owned 22,366 shares of the company’s stock, valued at $5,985,141.60. This trade represents a 3.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 129,164 shares of company stock worth $34,538,578. 13.70% of the stock is owned by insiders.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.